Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of DYN is 37 and suggests 118% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell